A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
ConditionNon-Small Cell Lung Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAbbisko Therapeutics Co, Ltd
About this trial
This is a multicenter, open-label phase 2 study that will enroll KRASG12C mutated patients with locally advanced or metastatic NSCLC, receiving treatment (ABSK043 in combination with Glecirasib) in a 21-day combination cycle.
Eligibility criteria
Qualifiers
Prior to any protocol- specific procedures are performed, the patient should understand and voluntarily sign and date the written informed consent form.
Gender was not limited patients aged ≥18 years at the time of signing the informed consent.
Histologically or cytologically confirmed locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC).
Prior treatment requirements for patients in cohort (Part B) are the same as those for patients in (Part A);
Disqualifiers
Histological or cytological evidence of small cell lung cancer or neuroendocrine carcinoma components.
Toxicities from prior antitumor therapy have not returned to baseline or stabilized.
Patients with active brain metastases.
The patient currently has active interstitial lung disease.
Trial design
Treatments tested in this trial
- ABSK043 in combination with Glecirasib
Treatment groups
86 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov